Comparison
Sermorelin vs CJC-1295
Two GHRH analogues on the same receptor. How long each survives in the body is the difference, and it changes both the schedule and the shape of what comes out.
Both copy growth-hormone-releasing hormone and both act on the same receptor. The difference is stability: sermorelin is cleared in minutes, CJC-1295 was engineered to resist the enzyme that does the clearing.
That produces genuinely different behaviour. A very short-acting analogue gives a brief pulse close to the natural shape. A longer-acting one holds the baseline up for longer, which is either the point or the problem depending on which argument you believe.
One naming trap to flag. CJC-1295 with DAC and CJC-1295 without it are different molecules with very different half-lives and schedules, and the unqualified name gets used for both.
| Attribute | Sermorelin | CJC-1295 |
|---|---|---|
| Receptor | GHRH | GHRH |
| Evidence level | Approved elsewhere | Early human |
| Half-life | Minutes | About 30 minutes without DAC; around a week with it |
| Dosing frequency | Once daily, usually at night | Once daily without DAC; weekly with it |
| Pulse shape | Brief, close to natural | Longer elevation |
Things worth knowing
- Buy the wrong CJC-1295 and your schedule matches nothing written about it. Check whether a vendor's product carries DAC before you follow any protocol you have read.
- A closer-to-natural pulse is a mechanistic argument, not a measured outcome. No study in healthy adults has compared the two on anything you would actually notice.
- Both are usually paired with a ghrelin-receptor secretagogue rather than run alone.
Full profile
Sermorelin
The original GHRH analogue, and the only one here that once held FDA approval, withdrawn for commercial reasons and not for safety.
Full profile
CJC-1295
A GHRH analogue that raises growth hormone by amplifying the body's own release signal. Sold in two forms whose durations differ by two orders of magnitude.
Related
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.